Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

AMERITOX, LLC

NPI: 1245561349 · GREENSBORO, NC 27409 · Clinical Medical Laboratory · NPI assigned 01/29/2010

$3.87M
Total Medicaid Paid
262,267
Total Claims
220,186
Beneficiaries
48
Codes Billed
2018-01
First Month
2018-04
Last Month

Provider Details

Authorized OfficialGARDNER, TODD (CFO)
Parent OrganizationAMERITOX, LLC
NPI Enumeration Date01/29/2010

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 262,267 $3.87M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 32,880 26,362 $954K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 10,981 8,517 $798K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 11,132 9,402 $662K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 9,005 5,754 $447K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,620 1,718 $254K
80332 5,672 4,796 $53K
80373 7,729 6,965 $44K
80354 9,083 7,894 $38K
80346 9,263 8,058 $37K
80356 9,424 8,212 $34K
80365 9,262 8,068 $33K
83992 8,600 7,481 $33K
80324 9,346 8,142 $32K
80338 4,613 4,185 $31K
80363 8,216 7,083 $30K
80353 9,242 8,033 $29K
80355 5,894 5,192 $28K
80344 4,723 4,258 $28K
80366 4,726 4,255 $26K
80359 8,926 7,744 $26K
80357 4,284 3,775 $25K
80360 7,310 6,236 $25K
80372 4,025 3,562 $22K
80375 3,807 2,450 $21K
80323 2,839 2,633 $18K
80368 2,596 2,144 $17K
80339 2,563 2,362 $15K
80361 4,018 3,541 $15K
80335 1,654 1,344 $13K
80352 5,361 4,716 $11K
80371 5,276 4,667 $11K
80321 2,307 1,935 $11K
80369 1,674 1,359 $11K
80349 3,288 2,835 $10K
80320 1,696 1,388 $8K
80348 3,182 2,502 $8K
80358 1,903 1,544 $5K
84311 6,426 5,246 $3K
80374 389 362 $3K
80345 1,242 1,090 $2K
82570 6,428 5,249 $2K
83986 6,431 5,251 $1K
80325 324 315 $772.35
80329 104 104 $723.63
80362 1,710 1,390 $476.00
G0479 Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service 12 12 $0.00
80301 41 28 $0.00
80302 40 27 $0.00